Clinical and Molecular Hepatology

Article	Citations
KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease	149
Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma	117
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma	100
Trends in the prevalence of chronic liver disease in the Korean adult population, 1998–2017	79
Novel biomarkers for the management of chronic hepatitis B	77
Obesity and the risk of primary liver cancer: A systematic review and meta-analysis	72
The development of mesenchymal stem cell therapy in the present, and the perspective of cell-free therapy in the future	67
Recent updates on the management of autoimmune hepatitis	66
Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop	65
Application of transient elastography in nonalcoholic fatty liver disease	65
From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?	63
Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach	62
<i>Lactobacillus</i> attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosis	62
Global incidence and prevalence of nonalcoholic fatty liver disease	62
Current understanding of primary biliary cholangitis	61
KASL clinical practice guidelines for liver cirrhosis: Varices, hepatic encephalopathy, and related complications	61
Managing liver cirrhotic complications: Overview of esophageal and gastric varices	56
MAFLD enhances clinical practice for liver disease in the Asia-Pacific region	51
Stereotactic body radiation therapy for small (≤5 cm) hepatocellular carcinoma not amenable to curative treatment: Results of a single-arm, phase II clinical trial	48
Evidence-based clinical advice for nutrition and dietary weight loss strategies for the management of NAFLD and NASH	48
MAFLD: How is it different from NAFLD?	48
Non-alcoholic fatty liver disease increases risk of carotid atherosclerosis and ischemic stroke: An updated meta-analysis with 135,602 individuals	47
The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease	46
Autophagy and liver cancer	43
Comparison of LI-RADS 2018 and KLCA-NCC 2018 for noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging	43

Programmed cell death in alcohol-associated liver disease	42
The effect of diabetes and prediabetes on the prevalence, complications and mortality in nonalcoholic fatty liver disease	41
KASL clinical practice guidelines for management of chronic hepatitis B	41
Switching to systemic therapy after locoregional treatment failure: Definition and best timing	40
Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name	39
Hepatic Hippo signaling inhibits development of hepatocellular carcinoma	39
Recent advances in nonalcoholic fatty liver disease metabolomics	39
Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy	39
Substantial risk of recurrence even after 5 recurrence-free years in early-stage hepatocellular carcinoma patients	39
The association of the serum levels of myostatin, follistatin, and interleukin-6 with sarcopenia, and their impacts on survival in patients with hepatocellular carcinoma	38
Updates in the quantitative assessment of liver fibrosis for nonalcoholic fatty liver disease: Histological perspective	37
Optimizing the management of intermediate-stage hepatocellular carcinoma: Current trends and prospects	37
Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biology	37
Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease	37
Outcomes after liver transplantation in Korea: Incidence and risk factors from Korean transplantation registry	34
The effect of moderate alcohol drinking in nonalcoholic fatty liver disease	33
Scaling up the in-hospital hepatitis C virus care cascade in Taiwan	32
Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment	31
Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease	30
Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma	29
RNA interference as a novel treatment strategy for chronic hepatitis B infection	29
Inhibition of PI3K/Akt signaling suppresses epithelial-to-mesenchymal transition in hepatocellular carcinoma through the Snail/GSK-3/beta-catenin pathway	29
Endoplasmic reticulum stress and autophagy dysregulation in alcoholic and non-alcoholic liver diseases	29
COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis	29
Drug induced liver injury: East versus West – a systematic review and meta-analysis	29
Changes in the epidemiology and management of bacterial infections in cirrhosis	28
Nonalcoholic fatty liver disease and alcohol-related liver disease: From clinical aspects to pathophysiological insights	27
The management of post-transplantation recurrence of hepatocellular carcinoma	26
Hepatocellular carcinoma statistics in South Korea	26
Toward a complete cure for chronic hepatitis B: Novel therapeutic targets for hepatitis B virus	25
Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis	25
β-blockers in advanced cirrhosis: More friend than enemy	24
From intestinal dysbiosis to alcohol-associated liver disease	24
Three heads are better than two: Hepatitis B core-related antigen as a new predictor of hepatitis B virus-related hepatocellular carcinoma	24
Clinical outcomes of coronavirus disease 2019 in patients with pre-existing liver diseases: A multicenter study in South Korea	23
Fecal microbiota transplantation in alcohol related liver diseases	23
Anti-fibrotic treatments for chronic liver diseases: The present and the future	23
Acute-on-chronic liver failure as a major predictive factor for mortality in patients with variceal bleeding	23
Global and regional impacts of alcohol use on public health: Emphasis on alcohol policies	22
Low-level viremia and cirrhotic complications in patients with chronic hepatitis B according to adherence to entecavir	22
Persistence of intrahepatic hepatitis B virus DNA integration in patients developing hepatocellular carcinoma after hepatitis B surface antigen seroclearance	21
Crosstalk between tumor-associated macrophages and neighboring cells in hepatocellular carcinoma	21
Association of non-alcoholic fatty liver disease with incident dementia later in life among elder adults	21
Hepatocellular carcinoma incidence is decreasing in Korea but increasing in the very elderly	20
Loss-of-function HSD17B13 variants, non-alcoholic steatohepatitis and adverse liver outcomes: Results from a multi-ethnic Asian cohort	20
Alcohol and hepatocarcinogenesis	20
Surgery versus radiofrequency ablation in patients with Child- Pugh class-A/single small (≤3 cm) hepatocellular carcinoma	20
Non-alcoholic fatty liver disease: Definition and subtypes	19
Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B	19
Radiation-induced abscopal effect and its enhancement by programmed cell death 1 blockade in the hepatocellular carcinoma: A murine model study	19

Obesity and binge alcohol intake are deadly combination to induce steatohepatitis: A model of high-fat diet and binge ethanol intake	19
Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Chinese perspective	18
Impact of everolimus on survival after liver transplantation for hepatocellular carcinoma	18
Clinical application of ultrasonography-guided percutaneous liver biopsy and its safety over 18 years	17
Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: A propensity score-matched analysis	17
Impact of diabetes, obesity, and dyslipidemia on the risk of hepatocellular carcinoma in patients with chronic liver diseases	17
Imaging diagnosis of hepatocellular carcinoma: Future directions with special emphasis on hepatobiliary magnetic resonance imaging and contrast-enhanced ultrasound	17
Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF- κB signaling pathways	16
Impact of nationwide hepatocellular carcinoma surveillance on the prognosis in patients with chronic liver disease	16
Emerging medical therapies for severe alcoholic hepatitis	16
The best predictive model for hepatocellular carcinoma in patients with chronic hepatitis B infection	16
Baveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients	15
Prevalence trends of non-alcoholic fatty liver disease among young men in Korea: A Korean military population-based cross-sectional study	15
The role of transjugular intrahepatic portosystemic shunt in patients with portal hypertension: Advantages and pitfalls	15
New next-generation microwave thermosphere ablation for small hepatocellular carcinoma	15
Intrahepatic cholangiocarcinoma: Tumour heterogeneity and its clinical relevance	15
Interaction between sarcopenia and nonalcoholic fatty liver disease	15
Risk factors in nonalcoholic fatty liver disease	15
The usefulness of metabolic score for insulin resistance for the prediction of incident non-alcoholic fatty liver disease in Korean adults	15
Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases	14
Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease	14
Comparisons between non-alcoholic steatohepatitis and alcohol-related hepatocellular carcinoma	14
Serum lipocalin-2 is a potential biomarker for the clinical diagnosis of nonalcoholic steatohepatitis	14
Screening strategy for non-alcoholic fatty liver disease	14
Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives	13
Limited expression of TLR9 on T cells and its functional consequences in patients with nonalcoholic fatty liver disease	13
Gut-derived lipopolysaccharide promotes alcoholic hepatosteatosis and subsequent hepatocellular carcinoma by stimulating neutrophil extracellular traps through toll-like receptor 4	13
Global burden of primary liver cancer and its association with underlying aetiologies, sociodemographic status, and sex differences from 1990–2019: A DALY-based analysis of the Global Burden of Diseas	13
Serum fibrosis index-based risk score predicts hepatocellular carcinoma in untreated patients with chronic hepatitis B	13
Comparison between obese and non-obese nonalcoholic fatty liver disease	13
Alcohol associated liver cirrhotics have higher mortality after index hospitalization: Long-term data of 5,138 patients	13
Role of cytoglobin, a novel radical scavenger, in stellate cell activation and hepatic fibrosis	12
Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region	12
Current and future strategies for the treatment of chronic hepatitis C	12
Metabolic disease as a risk of hepatocellular carcinoma	12
U-shaped relationship between urea level and hepatic decompensation in chronic liver diseases	12
Predictors of steroid non-response and new approaches in severe alcoholic hepatitis	12
Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future	12
Current knowledge about biomarkers of acute kidney injury in liver cirrhosis	11
Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis	11
Approaches to quantifying hepatitis B virus covalently closed circular DNA	11
Is liver biopsy still useful in the era of non-invasive tests?	11
The latest global burden of liver cancer: A past and present threat	11
Direct comparison of biopsy techniques for hepatic malignancies	11
Sarcopenia and blood myokine levels as prognostic biomarkers in patients with liver cirrhosis or hepatocellular carcinoma	11
Association between serum tumor necrosis factor-α and sarcopenia in liver cirrhosis	11
Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future	11
The dilemma of differentiating between acute hepatitis B and chronic hepatitis B with acute exacerbation: Is quantitative serology the answer?	11
Nonalcoholic fatty liver disease and non-liver comorbidities	10
Systematic review with meta-analysis: Non-alcoholic fatty liver disease and the association with pregnancy outcomes	10
Cause of death and cause-specific mortality for primary liver cancer in South Korea: A nationwide population-based study in hepatitis B virus-endemic area	10
Liver transplantation for non-alcoholic fatty liver disease: indications and post-transplant management	10
Development and prognosis of hepatocellular carcinoma in patients with diabetes	10
Roles of the complement system in alcohol-induced liver disease	10
The cut-off value of transient elastography to the value of hepatic venous pressure gradient in alcoholic cirrhosis	10
Long-term prognosis and management of hepatocellular carcinoma after curative treatment	10
Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase	10
A cost-effectiveness study of universal screening for hepatitis C virus infection in South Korea: A societal perspective	10
Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials	10
Long non-coding RNAs in liver diseases: Focusing on nonalcoholic fatty liver disease, alcohol-related liver disease, and cholestatic liver disease	10
Effect of moderate-to-severe hepatic steatosis on neutralising antibody response among BNT162b2 and CoronaVac recipients	9
Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis	9
Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity	9
Liver-lung axes in alcohol-related liver disease	9
Current status and outcome of liver transplantation in South Korea	9
Clinical practice guideline and real-life practice in hepatocellular carcinoma: A Korean perspective	9
Deep learning-based prediction of molecular cancer biomarkers from tissue slides: A new tool for precision oncology	9
Impacts of muscle mass dynamics on prognosis of outpatients with cirrhosis	9
Statin and aspirin for chemoprevention of hepatocellular carcinoma: Time to use or wait further?	9
Nonalcoholic fatty liver disease and early prediction of gestational diabetes mellitus using machine learning methods	9
Development of hepatocellular carcinoma in treated and untreated patients with chronic hepatitis B virus infection	9
Continuing besifovir dipivoxil maleate versus switching from tenofovir disoproxil fumarate for treatment of chronic hepatitis B: Results of 192-week phase 3 trial	9
Cost-effectiveness of chronic hepatitis C screening and treatment	9
Hepatocytes infected with hepatitis C virus change immunological features in the liver microenvironment	9
Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review	9
History and future of hepatitis B virus control in South Korea	8
Prediction models of hepatocellular carcinoma recurrence after liver transplantation: A comprehensive review	8
The emerging roles of extracellular vesicles as intercellular messengers in liver physiology and pathology	8
Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis	8
Identification of high-risk subjects in nonalcoholic fatty liver disease	8

Wnt signaling in liver regeneration, disease, and cancer	8
Management of refractory ascites	8
Use of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment	8
Association between new-onset liver cirrhosis and suicide risk in South Korea: A nationwide cohort study	8
Genetics in non-alcoholic fatty liver disease: The role of risk alleles through the lens of immune response	8
The impact of unrestricted access to direct-acting antiviral among incarcerated hepatitis C virus-infected patients	8
Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Taiwan perspective	8
Hepatitis B virus pre-genomic RNA and hepatitis B core-related antigen reductions at week 4 predict favourable hepatitis B surface antigen response upon long-term nucleos(t)ide analogue in chronic hep	8
Association of Visceral Fat Obesity, Sarcopenia, and Myosteatosis with Non-Alcoholic Fatty Liver Disease without Obesity	7
Acute hepatitis C virus infection: clinical update and remaining challenges	7
Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease	7
Oxidative stress and glutamate excretion in alcoholic steatosis: Metabolic synapse between hepatocyte and stellate cell	7
Global prevalence of depression and anxiety in patients with hepatocellular carcinoma: Systematic review and meta-analysis	7
Management of liver diseases during the pandemic of coronavirus disease-19	7
Overview of Asian clinical practice guidelines for the management of hepatocellular carcinoma: An Asian perspective comparison	7
Clinical practice guidelines and real-life practice on hepatocellular carcinoma: the Hong Kong perspective	7
Targeting epithelial-mesenchymal transition pathway in hepatocellular carcinoma	7
Non-alcoholic fatty liver disease and the risk of dementia: A meta-analysis of cohort studies	7
Liver graft from donation after circulatory death donor: Real practice to improve graft viability	7
Alcohol-related cirrhosis: The most challenging etiology of cirrhosis is more burdensome than ever	7
Significant down-regulation of growth hormone receptor expression revealed as a new unfavorable prognos- tic factor in hepatitis C virus-related hepatocellular carcinoma	7
Clinical significance of the discrepancy between radiological findings and biochemical responses in atezolizumab plus bevacizumab for hepatocellular carcinoma	6
Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments	6
Acute-on-chronic liver failure: Terminology, mechanisms and management	6
Update on liver disease management during the pandemic of coronavirus disease 2019 (COVID-19): 2021 KASL guideline	6
Eating, diet, and nutrition for the treatment of non-alcoholic fatty liver disease	6
Hepatitis B core-related antigen: A novel and promising surrogate biomarker to guide anti-hepatitis B virus therapy	6
Should you advocate for hepatocellular carcinoma surveillance in patients with alcohol-related liver disease or non-alcoholic fatty liver disease?	6
Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future	6
Waiting for the changes after the adoption of steatotic liver disease	6
Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity	6
Treatment of direct oral anticoagulants in patients with liver cirrhosis and portal vein thrombosis	6
Galectin-3 inhibits cardiac contractility via a tumor necrosis factor alpha-dependent mechanism in cirrhotic rats	6
The cutoff of transient elastography for the evaluation of portal hypertension should be different according to the etiology?	6
Negligible risk of hepatocellular carcinoma in chronic hepatitis B patients in immune-tolerant phase: Myth or fact	6
Optimal sequence of systemic therapy after sorafenib failure in patients with hepatocellular carcinoma	5
Non-alcoholic fatty liver disease: the pathologist’s perspective	5
Diagnosis of hepatocellular carcinoma: Which MRI contrast agent? Which diagnostic criteria?	5
Surveillance for hepatocellular carcinoma: It is time to move forward	5
Protective association of Klotho rs495392 gene polymorphism against hepatic steatosis in non-alcoholic fatty liver disease patients	5
Taurocholic acid promotes hepatic stellate cell activation via S1PR2/p38 MAPK/YAP signaling under cholestatic conditions	5
An analysis of polygenic risk scores for non-alcoholic fatty liver disease	5
Another oral antiviral treatment, but still far away from hepatitis B virus cure	5
Regulated differentiation of stem cells into an artificial 3D liver as a transplantable source	5
Effects of interleukin-17 inhibitors on hepatic fibrosis index in patients with psoriasis and metabolic dysfunction-associated fatty liver disease: Directed acyclic graphs	5
The independent effect of exercise on biopsy-proven non-alcoholic fatty liver disease: A systematic review	4
Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response	4
The emerging age-pattern changes of patients with hepatocellular carcinoma in Korea	4
Evidence-based hyponatremia management in liver disease	4
Single-cell phenotypes of peripheral blood immune cells in early and late stages of non-alcoholic fatty liver disease	4
Microbiome and metabolomics in alcoholic liver disease	4
Non-invasive tests-based risk stratification: Baveno VII and beyond	4
The role of different viral biomarkers on the management of chronic hepatitis B	4
Classification of microvascular invasion of hepatocellular carcinoma: correlation with prognosis and magnetic resonance imaging	4
Nonalcoholic fatty liver disease-based risk prediction of adverse pregnancy outcomes: Ready for prime time?	4
Outcomes of Hepatitis C Virus Treatment with Ledipasvir/Sofosbuvir in Mongolian Population: Successes and Challenges Facing Scale-up of Care	4
Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and future	4
Safety considerations for withdrawal of nucleos(t)ide analogues in patients with chronic hepatitis B: First, do no harm	4
Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Japanese perspective	4
Adding to the confusion in more than just the name	4
The effects of moderate alcohol consumption on non-alcoholic fatty liver disease	4